The MAD portion of the Phase 1 trial is designed to test a once-daily dosing of CRB-913 for 7 days. Similarly to the SAD study, the MAD study is undertaken with healthy volunteers and focuses on safety, tolerability and PK of increasing doses of CRB-913. The study is being conducted in the United States. "The data collected to date shows a satisfactory translation from pre-clinical models to the clinical settings," said Yuval Cohen, PhD, CEO of Corbus. "An absence of treatment-related neuropsychiatric event ...